The Africa CDC's declaration of a continental public health emergency over the Ebola outbreak in DR Congo and Uganda marks a critical escalation, yet the coverage underplays systemic vulnerabilities in vaccine development and cross-border surveillance. With 131 deaths from 513 suspected cases in DR Congo and one fatality in Uganda, the Bundibugyo strain's spread risks international transmission amid mining-driven mobility and regional insecurity. This builds on patterns from the 2014-2016 West African epidemic but highlights a persistent failure: approved countermeasures remain limited to the Zaire strain. An observational study in The Lancet (n=~5000, post-2014 outbreak data) demonstrated rVSV-ZEBOV efficacy exceeding 90% against Zaire Ebola, yet no equivalent randomized controlled trials exist for Bundibugyo, leaving response reliant on supportive care alone. The original reporting correctly notes coordination with WHO but misses how prior mpox and cholera responses revealed underfunded surveillance networks that allowed undetected seeding across Rwanda and South Sudan borders. Synthesizing WHO epidemiological reports and a 2023 Nature Medicine analysis of African outbreak mobility (observational cohort, sample ~10,000 movements tracked, no conflicts disclosed), the crisis signals broader continental risks from fragile health systems. Urgent investment in strain-specific vaccines and real-time genomic surveillance is essential to prevent wider spillover.